Targeted therapies in solid tumours: Results and promises;Le "targeted therapies" nei tumori solidi: Risultati e promesse

Minerva Medica

Volumn 98, Issue 5, 2007, Pages 603-623

  Pantaleo, M A ^a   Saponara, M ^a   Nannini, M ^a   Biasco, G ^a,b  

^a L and A Seràgnoli Hematology and Oncological Sciences Institute   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antibodies, monoclonal; Neoplasms; Protein kinase inhibitors; Receptor, epidermal growth factor

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GROWTH FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN KINASE INHIBITOR; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATHOGENESIS; PERIORBITAL EDEMA; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISCOLORATION; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PIPERAZINES; PYRIMIDINES;

EID: 36949005868     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bejamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
2. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overespressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004;22:1071-7.
3. Burstein Harold J, Harris Lyndsay N, Marcom P Kelly, Lambert-Falls R, Havlin K, Overmoyer B et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overespressing metastatic breast cancer: multi-center phase II trial with clinical outcomes, analysis of serum tumour markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95.
4. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74.
5. Chia S, demons M, Martin LA, Rodgers A, Gelmon K, Pond GR et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overespressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24:2773-8.
6. Hurley J, Doliny P, Reis I, Silvia O, Gomez-Fernandez C, Velez P et al. Docetaxel, cisplatin and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831-8.
7. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overespressing metastatic breast cancer. J Clin Oncol 2006;24:2786-92.
8. Piccard-Gebhart MJ, Proctor M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005;353:1659-72.
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005;353:1673-84.
10. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.
11. Ewer MS, Lippam SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-3.
12. Than-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, HER-2 overespressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-9.
13. Seidam A, Hudis C, Pierri MK, Shah S, Paton V, Ashby M et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
14. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colon rectal cancer that expresses the epidermal growth factor receptor. Prog Proc Am Soc Clin Oncol 2001;20:3a.
15. Saltz LB, Meropol NJ, Loeherer Sr PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colon rectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colon rectal cancer. N Engl J Med 2004;351:337-45.
17. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A et al. Cetuximab shows activity in colon rectal cancer patients with tumours that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
18. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F et al. Gene copy number for epidermal growth factor receptor (EGFr) and clinical response to anti EGFr treatment in colon rectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
19. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P et al. Multicenter phase II trial and translational study of cetuximab in metastatic colon rectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol 2006;24:4914-21.
20. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G et al. Phase II randomized trial comparing bevacizumab plus fluoruracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colon rectal cancer. J Clin Oncol 2003;21:60-5.
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluoruracil, and leucovorin for metastatic colon rectal cancer. N Engl J Med 2004;350:2335-42.
22. Hochster HS, Welles L, Hart L, Ramanathan RK, Hainsworth J, Jirau-Lucca G et al. Bevacizumab with oxaliplatin based-chemotherapy in the first line therapy of metastatic colon rectal cancer: preliminary results of the randomized TREE-2 trial. GI Proc Am Soc Clin Oncol 2005;24:a241.
23. Fernando N, Yu D, Morse M, Blobe G, Odogwu L, Crews J et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colon rectal cancer. Proc Am Soc Clin Oncol 2005;24:a289.
24. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
25. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advaced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
26. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
27. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
28. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
29. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
30. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
31. Lynch TJ, Daphne MD, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
32. Eberhard DA, Johson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
33. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
34. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
35. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
36. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
37. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shan MH, Verweij J et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
38. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.